Literature DB >> 11349735

Transplanted MHC class I-deficient nonobese diabetic mouse islets are protected from autoimmune injury in diabetic nonobese recipients.

S Prange1, P Zucker, A M Jevnikar, B Singh.   

Abstract

The injury of transplanted islets may occur by both autoimmune and alloimmune processes directed against MHC targets. To examine the role of MHC class I in islet graft injury, we transplanted syngeneic and allogeneic beta2-microglobulin-deficient islets into diabetic nonobese diabetic (NOD) mice. Loss of graft function was observed within 14 days using allogeneic C57BL/6 and BALB/c MHC class I deficient as well as wild-type MHC class I-bearing NOD donor islets. However, islets isolated from MHC class I-deficient NOD mice (NOD-B2 m-/-) survived indefinitely when transplanted under the kidney capsule of diabetic NOD recipients. Transplanted NOD-B2 m-/- islets were surrounded by a nondestructive periinsular infiltrate that expressed interleukin-4 in addition to interferon-gamma. These studies demonstrate the primary role of MHC class I molecules in causing autoimmune destruction or recurrent diabetes in transplanted islets.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11349735     DOI: 10.1097/00007890-200104150-00025

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  11 in total

Review 1.  Prospects for the prevention and reversal of type 1 diabetes mellitus.

Authors:  Nikolai Petrovsky; Diego Silva; Desmond A Schatz
Journal:  Drugs       Date:  2002       Impact factor: 9.546

2.  Nasal administration of CTB-insulin induces active tolerance against autoimmune diabetes in non-obese diabetic (NOD) mice.

Authors:  C Aspord; C Thivolet
Journal:  Clin Exp Immunol       Date:  2002-11       Impact factor: 4.330

3.  HLA engineering of human pluripotent stem cells.

Authors:  Laura Riolobos; Roli K Hirata; Cameron J Turtle; Pei-Rong Wang; German G Gornalusse; Maja Zavajlevski; Stanley R Riddell; David W Russell
Journal:  Mol Ther       Date:  2013-04-30       Impact factor: 11.454

Review 4.  The use of peptide-major-histocompatibility-complex multimers in type 1 diabetes mellitus.

Authors:  Greg S Gojanovich; Sabrina L Murray; Adam S Buntzman; Ellen F Young; Benjamin G Vincent; Paul R Hess
Journal:  J Diabetes Sci Technol       Date:  2012-05-01

5.  HLA Class I Depleted hESC as a Source of Hypoimmunogenic Cells for Tissue Engineering Applications.

Authors:  Zaruhi Karabekian; Hao Ding; Gulnaz Stybayeva; Irina Ivanova; Narine Muselimyan; Amranul Haque; Ian Toma; Nikki G Posnack; Alexander Revzin; David Leitenberg; Michael A Laflamme; Narine Sarvazyan
Journal:  Tissue Eng Part A       Date:  2015-09-10       Impact factor: 3.845

6.  Detection of vasostatin-1-specific CD8(+) T cells in non-obese diabetic mice that contribute to diabetes pathogenesis.

Authors:  E Nikoopour; O Krougly; E Lee-Chan; S M Haeryfar; B Singh
Journal:  Clin Exp Immunol       Date:  2016-07-28       Impact factor: 4.330

7.  Beta cell MHC class I is a late requirement for diabetes.

Authors:  Emma E Hamilton-Williams; Stephanie E Palmer; Brett Charlton; Robyn M Slattery
Journal:  Proc Natl Acad Sci U S A       Date:  2003-05-15       Impact factor: 11.205

8.  CD4+ T cells are sufficient to elicit allograft rejection and major histocompatibility complex class I molecule is required to induce recurrent autoimmune diabetes after pancreas transplantation in mice.

Authors:  Zhidan Xiang; Lian-Li Ma; Santhakumar Manicassamy; Balaji B Ganesh; Phillip Williams; Ravi Chari; Anita Chong; Deng-Ping Yin
Journal:  Transplantation       Date:  2008-04-27       Impact factor: 4.939

Review 9.  Engineering universal cells that evade immune detection.

Authors:  Robert Lanza; David W Russell; Andras Nagy
Journal:  Nat Rev Immunol       Date:  2019-08-15       Impact factor: 53.106

Review 10.  Making the most of major histocompatibility complex molecule multimers: applications in type 1 diabetes.

Authors:  Greg S Gojanovich; Paul R Hess
Journal:  Clin Dev Immunol       Date:  2012-05-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.